| 摘要 |
A cell therapeutic composition comprising stem cells derived from umbilical cord blood of CD34 negative, CD45 positive, CD31 positive, CD13 positive, CD90 positive and CD117 positive is provided to improve and treat spinal cord injury and treat patients suffering from spinal paralysis having no alternative therapy. A cell therapeutic composition for treating and improving spinal cord injury comprises stem cells derived from umbilical cord blood of CD34 negative, CD45 positive, CD31 positive, CD13 positive, CD90 positive and CD117 positive. A cell therapeutic composition comprises stem cells derived from umbilical cord blood of CD34 negative, CD45 positive, CD31 positive, CD13 positive, CD90 positive and CD117 positive which are obtained by: (a) adding an anticoagulant to umbilical cord blood of CD34 negative, which is pure umbilical cord blood within 24 hours after delivery and has a volume of more than 45ml per one unit; (b) after diluting the umbilical cord blood using a low glucose DMEM(Dulbecco's Modified Eagle Media) culture medium, centrifuging it to obtain mononuclear cells; and (c) culturing the obtained mononuclear cells in a low glucose DMEM including 10% of FBS(fetal bovine serum) for 20 days. |
